Females of child-bearing potential cannot be pregnant or breast-feeding; female participants > 10 years of age or post-menarche must have a negative serum or urine pregnancy test prior to enrollment
A negative serum pregnancy test is required for female participants of child bearing potential (?13 years of age or after onset of menses)
A negative serum pregnancy test is required for female participants of child bearing potential (?13 years of age or after onset of menses)
Pregnant or breast feeding; females of child-bearing potential must test negative for pregnancy at the time of enrollment based on a urine or serum pregnancy test; both male and female patients of reproductive potential must agree to use a reliable method of birth control, during the study and for 3 months following the last dose of study drug
Female subjects with child bearing potential must have a negative pregnancy test at screening; child bearing potential is defined as sexually active patients with menses less than 1 year prior to enrollment, < 65 years of age, have no history of oophorectomy or hysterectomy
Male and female patient of child bearing potential, (for female entering the study after a menstrual period and who have a negative pregnancy test at baseline) must agree to use two methods (one for the patient and one for the partner) of medically acceptable forms of contraception during the study and for 3 months after the last treatment intake.
Female patients of child bearing potential must have negative serum pregnancy test at screening
Female subjects of child-bearing potential must have a negative serum pregnancy test within 14 days of the first day of drug dosing.
Female patients of child bearing potential must not be breastfeeding or pregnant as evidenced by a negative pregnancy test
Female patients of child bearing potential must have a negative pregnancy test within 7 days from the time of registration
A negative urine or serum pregnancy test is required for female subjects of child bearing potential (onset of menses or ?13 years of age).
Female patients of childbearing potential must have a negative serum pregnancy test and agree to use at least one form of pregnancy prevention during the study and for at least one month after treatment discontinuation; for the purposes of this study, child- bearing potential is defined as: all female patients that were not in post-menopause for at least one year or are surgically sterile (site-specific criteria applying to Avera only)
Pregnancy (patients of child-bearing age must be appropriately tested before chemotherapy)
Female patients who are not of child-bearing potential and female patients of child-bearing potential who agree to use adequate contraceptive measures or abstain from heterosexual intercourse during the entire study treatment period and for 4 months after the last dose of study drug, who are not breastfeeding, and who have had a negative serum/urine pregnancy test ?7 days prior to dosing
Patients with the potential for pregnancy or impregnating their partner must agree to follow acceptable birth control methods to avoid conception; female patients of child-bearing potential must have negative pregnancy test
AUTOLOGOUS APHERESIS: For females of child bearing age:\r\n* Not lactating with intent to breastfeed\r\n* Not pregnant with negative serum pregnancy test within 7 days prior to enrollment
Female patients who are not of child-bearing potential and female patients of child-bearing potential who have a negative serum pregnancy test within 3 days prior to cycle 1, day 1
Female patients who are not of child-bearing potential, and female patients of child-bearing potential who agree to use adequate contraceptive measures.
Fertility requirements\r\n* Female patients with child bearing potential must have a negative pregnancy test at least 7 days before starting treatment drugs\r\n* Male patients must agree to use an adequate method of contraception for the duration of the study and for 7 months afterwards\r\n* Female patients must be either posy-menopausal, free from menses >= 2 years (yrs), surgically sterilized, willing to use two adequate barrier methods of contraception to prevent pregnancy, or agree to abstain from sexual activity starting from screening and for 5 months afterwards\r\n* Female patients of child bearing potential must agree to comply with the fertility and pregnancy test requirements dictated by the Rev-Assist program
Female patients of child bearing potential must have a negative urine or serum pregnancy test within 7 days from the time of registration
If female and of child-bearing potential, must:
Women who are pregnant or lactating; patients must be either surgically sterile (via hysterectomy or bilateral tubal ligation), post-menopausal or using acceptable methods of contraception if they are of child bearing potential; female patients of child bearing potential must have a negative serum or urine pregnancy test within 7 days prior to starting drug; breastfeeding should be discontinued if the mother is treated with radiation
If a female of child-bearing age, have a negative pregnancy test prior to each ultrasound exam
Female patients of child-bearing potential must have a negative pregnancy test and use at least one form of contraception as approved by the investigator for 4 weeks prior to initiating study treatment and 4 months after the last dose of study drug. For the purposes of this study, child-bearing potential is defined as \all female patients unless they are post-menopausal for at least 3 years or surgically sterile\;
Not pregnant; if female with child bearing potential, must be confirmed by negative serum or urine pregnancy test within 14 days prior to enrollment
Women of child-bearing potential must have a negative serum or urine pregnancy test. Male and female patients must agree to use acceptable contraceptive methods for the duration of the study and for at least one month after the last drug administration.
If the patient is a sexually active female of child bearing potential whose partner is male, or if the patient is a sexually active male whose partner is a female of child bearing potential, the patient must agree to use appropriate contraceptive measures for the duration of the treatment of the tumor and for 6 months afterwards; female patients of child bearing potential must have a negative serum pregnancy test within 48 hours of starting study treatment
Female patients of child bearing age must have a negative pregnancy test, be surgically sterile or post-menopausal >= 1 year (yr)
Female subjects: if of child bearing potential, must have negative serum or urine pregnancy test within 7 days of enrollment
Pregnant or lactating; adequate birth control must be used if of child bearing potential per institutional policy; negative pregnancy test in female patients of child-bearing potential per institutional policy; post-menopausal women must have had amenorrhea for at least 18 months to be considered non-child bearing
If the patient is a sexually active female of child bearing potential, whose partner is male, or if the patient is a sexually active male, whose partner is a female of child bearing potential, the patient must agree to use appropriate contraceptive measures for the duration of the treatment of the tumor and for 6 months afterwards as stated in the informed consent; female patients of child bearing potential must have a negative serum pregnancy test at the time of screening and within 48 hours of starting the D2C7-IT infusion
Women of child-bearing potential must have a negative serum or urine pregnancy test. Male and female patients must agree to use acceptable contraceptive methods for the duration of the study and for at least one month after the last drug administration.
A negative urine pregnancy test is required for female subjects of child bearing potential (onset of menses or ?13 years of age).
DONOR: Female donors of child-bearing potential (> 7 yo) must have a negative serum or urine beta-HCG test within three weeks of marrow donation and agree to utilize contraception if sexually active
Female patients of child-bearing potential must have a negative pregnancy test within 14 days prior to study registration
Not pregnant; if female with child bearing potential, must be confirmed by negative serum or urine pregnancy test within 14 days prior to enrollment
Patients must not be pregnant or breast-feeding. Female patients of child-bearing potential must have a negative pregnancy test performed within 72 hours prior to randomization. Women of child-bearing potential must agree not to become pregnant while participating in the study.
Pregnancy test (serum or urine): negative for females of childbearing potential: a female is considered to be of child bearing potential unless she has had a tubal ligation or is postmenopausal (without a menstrual period for at least one year)
Lactating, breastfeeding, or positive pregnancy test for female patients of child-bearing potential.
Female patients of child-bearing potential must agree to practice abstinence or use dual methods of contraception during treatment and for 30-days after the last dose of carfilzomib and have a negative serum pregnancy test at screening
Female subjects of child bearing age must have negative serum pregnancy test at study entry
Female patients of child-bearing potential must have a negative pregnancy test.
Female subjects: if of child bearing potential, must have negative serum or urine pregnancy test within 7 days of enrollment
Female subjects who are pregnant intend to become pregnant or are nursing; female subjects with child-bearing potential must have a negative pregnancy test within one week of enrollment
The participant, if female and of child-bearing potential, must have a negative pregnancy test.
MF PATIENTS: Female patients of child-bearing potential (FOCBP) must have a negative serum beta-HCG pregnancy test within 7 days prior to registration
If female of child-bearing potential, have a negative pregnancy test =< 14 days prior to registration
Female patients who are not of child-bearing potential, and fertile female patients of child-bearing potential who agree to use adequate contraceptive measures, who are not breastfeeding, and who have a negative serum or urine pregnancy test within 72 hours prior to start of randomization
The participant, if female and of child-bearing potential, must have a negative serum or urine pregnancy test within 7 days prior to randomization.
Female patients who are not of child-bearing potential, and female patients of child-bearing potential who have a negative serum pregnancy test at study screening; a tubal ligation is sufficient documentation that a patient is not of child bearing potential; female patients of child-bearing potential, and all male partners must consent to use a medically acceptable method of contraception throughout the study period and for 30 days after the last dose of either study drug
Fertility requirements:\r\n* Female patients with child bearing potential must have a negative pregnancy test within 7 days before starting treatment drugs\r\n* Male patients must agree to use an adequate method of contraception for the duration of the study and for 90 days after therapy discontinuation\r\n* Female patients must be either posy-menopausal, free from menses >= 2 years (yrs), surgically sterilized, willing to use two adequate barrier methods of contraception to prevent pregnancy, or agree to abstain from sexual activity starting from screening and continuing through 90 days after study therapy discontinuation\r\n* Female patients of child bearing potential must agree to comply with the fertility and pregnancy test requirements dictated by the Rev-Assist program
Female patients of child bearing potential must have negative serum pregnancy test
If female and of child-bearing potential, has negative pregnancy test within 14 days prior to treatment.
Female patients of child-bearing potential must have a negative pregnancy test within 14 days prior to registration
Women of child-bearing potential must have a negative serum or urine pregnancy test. Male and female patients must agree to use acceptable contraceptive methods for the duration of the study and for at least one month after the last drug administration.
Negative pregnancy test if female of child-bearing potential. Fertile patients must use effective contraception*.
Female patients who are pregnant or lactating – or planning to become pregnant within 6 months after the end of the treatment (female patients of child-bearing potential must have negative pregnancy test =< 72 hours before enrollment and randomization and must have a negative pregnancy test =< 72 hours prior to treatment start)
Female patients with child-bearing potential must have a negative serum or urine pregnancy test within 7 days of study enrollment; nursing mothers should discontinue nursing
Female candidates of child bearing potential that are pregnant (confirmed by positive pregnancy test)
A female of child-bearing potential, must have two negative urine pregnancy test results within 10 to 14 days prior to starting the first dose of vaccine and Revlimid pre-transplant
If female of child bearing potential, have a negative pregnancy test at screening
Not pregnant; if female with child bearing potential, must be confirmed by negative serum or urine pregnancy test within 14 days prior to enrollment
If female of child bearing potential, have a negative pregnancy test at screening
Female patients who are not of child-bearing potential, and female patients of child-bearing potential who agree to use adequate contraceptive measures and who have a negative serum pregnancy test within 1 week prior to initial study treatment. (See Appendix B)
Female patients who are pregnant or lactating or planning to become pregnant within 6 months after the end of the treatment (female patients of child-bearing potential must have negative pregnancy test =< 72 hours before registration)
Not pregnant; if female with child bearing potential, must be confirmed by negative serum or urine pregnancy test within 14 days prior to enrollment
Non-pregnant female at least 18 years of age. If the subject is of child-bearing age, must have a negative serum pregnancy test at baseline and must agree to practice an acceptable form of birth control while on the study.
Female patients of child-bearing potential must have a negative serum pregnancy test within 14 days prior to registration.
Female patients of child bearing age who have a positive pregnancy test
Female patients who are pregnant (female patients of child-bearing potential must have a negative serum pregnancy test =< 14 days prior to surgery or 15 to 30 days prior to surgery with a negative urine pregnancy test the morning of surgery)
Female participants of child-bearing potential must have a negative urine or serum pregnancy test at the time of the screening visit
Pregnant or nursing female subjects, or female subjects of child bearing potential who refuse to take a pregnancy test prior to their enrollment in this study
Female subjects of child bearing potential must have a negative pregnancy test prior to first dose of tocilizumab and must agree to practice effective contraception during the study
A negative urine pregnancy test is required for female subjects of child bearing potential (onset of menses or ?13 years of age).
Female patients of child-bearing potential must have a negative pregnancy test prior to enrollment
A negative serum or urine pregnancy test is required for female subjects of child bearing potential (onset of menses or ?13 years of age).
A negative urine pregnancy test is required for female participants of child bearing potential (?13 years of age).
Non-pregnant and non-lactating; patients of child-bearing potential must have a negative pregnancy test within 7 days prior to registration; perimenopausal patients must be amenorrheic > 12 months to be considered not of child-bearing potential
If a female of child-bearing potential, must have a negative pregnancy test
Females who are pregnant or breast-feeding at the time of screening will not be eligible for this study; female participants of child-bearing potential will have a urine or serum pregnancy test at the time of the screening visit
Females who are pregnant or breast-feeding at the time of screening will not be eligible for this study; female participants of child-bearing potential will have a urine or serum pregnancy test at the time of the screening visit
Negative pregnancy test if female of child-bearing age
Subject is male; or is a female who is either surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy), postmenopausal (> 1 years without menses), >= 60 years old, or of childbearing potential for whom a pregnancy test (with the results known prior to investigational product administration) is negative; a negative pregnancy test will be required for all female subjects with child bearing potential; if a false pregnancy test is suspected, e.g., perimenopausal condition, an obstetrician will be consulted to determine if she is/is not capable of becoming pregnant; female must also be non-lactating
If a female of child-bearing potential, must have a negative pregnancy test
Subject is male; or is a female who is either pre-menarchal, surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy), postmenopausal (> 1 years without menses), non-lactating, or of childbearing potential for whom a serum pregnancy test (with the results known prior to investigational product administration) is negative; a negative serum pregnancy test will be required for all female subjects with child bearing potential; if a false pregnancy test is suspected, e.g., perimenopausal condition, an obstetrician will be consulted to determine if she is/is capable of becoming pregnant
Pregnancy or breast feeding; a negative serum pregnancy test is required for all female subjects with child-bearing potential
Not pregnant; a negative serum pregnancy test is required for all female subjects with child-bearing potential
Subject is male; or is a female who is either pre-menarchal, surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy), postmenopausal (> 1 years without menses), non-lactating, or of childbearing potential for whom a serum pregnancy test (with the results known prior to investigational product administration) is negative; a negative serum pregnancy test will be required for all female subjects with child bearing potential; if a false pregnancy test is suspected, e.g., perimenopausal condition, an obstetrician will be consulted to determine if she is/is capable of becoming pregnant
If a female of child-bearing potential, must have a negative pregnancy test
All female participants with child bearing potential cannot be pregnant or nursing, as confirmed by serum pregnancy test; further, if the female patient is of child-bearing potential, she must agree with use birth control, including oral, injectable or mechanical contraception, abstinence, or vasectomy for 30 days following pimonidazole administration; female patients who become pregnant within six months after receiving the study treatment will be followed through birth or termination of the pregnancy; the Investigator or designee must report all pregnancies to the Sponsor or Sponsor’s authorized representative immediately after becoming aware of the event
If a female of child-bearing age, must have a negative pregnancy test
Non-pregnant and non-lactating; women of child-bearing potential must have a negative urine or serum pregnancy test prior to registration; peri-menopausal women must be amenorrheic >= 12 months prior to registration to be considered not of childbearing potential
Negative serum pregnancy test obtained for females of child-bearing potential within 28 days prior to step 2 registration
For females of child-bearing potential, negative serum or urine pregnancy test within 14 days prior to study registration
Negative serum pregnancy test in women of child-bearing potential within 7 days of day 1 (D1) of treatment
Refusal to take a pregnancy test prior to treatment if the patient is a woman with child bearing potential
Women of child-bearing potential must have a negative pregnancy test within 7 days of initiating study; (no childbearing potential is defined as age 55 years or older and no menses for two years or any age with surgical removal of the uterus and/or both ovaries)
Women of child bearing potential must have a negative serum pregnancy test result within 7 days prior to initiation of study drug
Negative pregnancy test for women of child bearing potential
Negative serum pregnancy test and using medically acceptable form of contraception if of child bearing potential
Negative serum or urine pregnancy test within 7 days prior to the first dose of ALRN-6924 for women of child-bearing potential
Negative pregnancy test in women of child bearing potential
Women of child-bearing potential must have a negative pregnancy test within 7 days of initiating study (no childbearing potential is defined as age 55 years or older and no menses for two years or any age with surgical removal of the uterus and/or both ovaries)
Females of child-bearing potential (FOCBP) must have a negative pregnancy test within 28 days prior to registration on study
Negative urine or serum pregnancy test performed =< 7 days prior to registration, for women of child bearing potential only
Negative pregnancy test in women of child-bearing potential
Negative pregnancy test for women of child bearing potential
Pregnant women are excluded from this study; breastfeeding women are also excluded; female subjects of child bearing potential must have a negative serum pregnancy test obtained prior to trial registration
Women of child bearing potential (WOCBP) must have a negative serum or urine pregnancy test within 5 days prior to randomization.
Women of child-bearing potential has negative pregnancy test prior to initiating study drug dosing
If the patient is a woman of child bearing potential (WOCBP), she has had a negative serum or urine pregnancy test within 1 week prior to treatment.
Women of child-bearing potential must have a negative pregnancy test
Women of child-bearing potential must have a negative pregnancy test
Women of child-bearing potential must have a negative pregnancy test
Women of child-bearing potential must have a negative pregnancy test because of the potentially dangerous effects of the treatment on the fetus.
Women of child-bearing potential must have a negative pregnancy test
Negative serum or urine pregnancy test for women with child-bearing potential
Women of child-bearing potential (WOCBP) must have a negative pregnancy test within 28 days before study enrollment
Females of child bearing potential must have a negative serum pregnancy test with 7 days prior to first dose of treatment and use 2 methods of contraceptives while on treatment
Positive pregnancy test in females of child-bearing potential or pregnant or currently breastfeeding
Women of child bearing potential must have a negative serum pregnancy test, not be nursing, and use acceptable contraception
Subjects who are pregnant or planning to become pregnant during the study; women of child bearing potential must have a negative pregnancy test
A negative pregnancy test will be required for all women of child bearing potential; breast feeding is not permitted
For females of child-bearing age, a negative pregnancy test.
Women of child-bearing potential must have a negative pregnancy test within 1 week of IORT treatment
CHEMOTHERAPY/CELL INFUSION ELIGIBILITY: For women of child-bearing potential, a negative serum pregnancy testing will be verified within 7 days prior to treatment
Pregnant or lactating women; women of child-bearing potential (WOCBP) must have a negative serum pregnancy test documented within 3 days prior to start of study drug
Women of child-bearing potential must have a negative pregnancy test; women of child-bearing potential are defined as all women who are not post-menopausal or who have not had a hysterectomy; postmenopausal will be defined as women over the age of 55 who have not had a menstrual period in at least 1 year
Women of childbearing potential must have a negative serum or urine pregnancy test at time of screening and confirmed within 3 days prior to treatment; women not of child-bearing potential will be defined as all women older than age 50 and anovulatory for 12 months
Women of child-bearing potential must have a negative pregnancy test
Women of child-bearing potential without a serum negative pregnancy test and not willing to refrain from sexual activity or to utilize an adeguate contraceptive methods during all the course of the study
Negative pregnancy test for women of child bearing potential
Women of child-bearing potential has negative pregnancy test within 72 hours of initiating study drug dosing
Women of child-bearing potential must have a negative pregnancy test 7 or fewer days from registration
Negative pregnancy test in women of child-bearing potential
(For both cohorts A and B): Women of child-hearing potential (WCBP) must have a negative pregnancy test within 3 days prior to the first dose of study treatment
Women of childbearing potential must have a negative serum or urine pregnancy test within 3 days prior to treatment; women not of child-bearing potential will be defined as all women older than age 50 and anovulatory for 12 months
Negative serum pregnancy test within 7 days of day 1 (D1) of treatment in women of child bearing potential
Pregnant or breastfeeding; women of child bearing potential must have a negative pregnancy test at screening
Pregnant or breastfeeding - women of child bearing potential must have a negative pregnancy test at screening
Females of child bearing potential must have a negative serum pregnancy test within 14 days prior to entrectinib dosing
Obtained =< 14 days prior to registration: Negative pregnancy test for persons of child-bearing potential
Negative pregnancy test for women of child-bearing potential within 48 hours prior to first dose of BMX-001.
Women of child-bearing potential must have a negative serum or urine pregnancy test.
Women of child bearing potential must have a negative urine or blood pregnancy test within 14 days of study enrollment
Women of child bearing potential: positive pregnancy test (serum)
Women of child-bearing potential must have a negative pregnancy test within 7 days of initiating study; (no childbearing potential is defined as age 55 years or older and no menses for two years or any age with surgical removal of the uterus and/or both ovaries)
Women of child-bearing potential must have a negative pregnancy test
Women of child-bearing potential must have a negative pregnancy test because of the potentially dangerous effects of the treatment on the fetus
Women of child bearing potential must have a negative pregnancy test; women of child-bearing potential are defined as all women except women who are post-menopausal or who have had a hysterectomy; postmenopausal will be defined as women over the age of 55 who have not had a menstrual period in at least 1 year
Women of child-bearing potential must have a negative pregnancy test
Women of child-bearing potential (WOCBP) must have a negative pregnancy test
Women of child-bearing potential must have a negative urinary or serum pregnancy test
Negative pregnancy test for women with child-bearing potential
Females of child-bearing potential must have a negative serum pregnancy test within 7 days of treatment.
Women of child-bearing potential (WOCBP) must have a negative serum pregnancy test at screening and a negative urine pregnancy test prior to administration of each dose of JTX-2011
Negative pregnancy test for women of child bearing potential
Women of child bearing potential must have a negative pregnancy test by urinalysis
Women of child?bearing potential (e.g. not post?menopausal or permanently sterilized women) must have a negative pregnancy test obtained within 14 days prior to registration; this is to prevent potential harm to the fetus by glyburide and radiotherapy
Women of child-bearing potential must have negative pregnancy test prior to initiating study drug treatment
Women of child-bearing potential must have a negative pregnancy test
Pregnant or lactating – women of child bearing potential must have a negative pregnancy test within 14 days of study treatment start
Pregnant or lactating women. Women of childbearing potential must have a urine pregnancy test proven negative within 14 days prior to randomization. Men and women of child-bearing potential must agree to use adequate contraception.
Women of child-bearing potential (WOCBP) must have a negative pregnancy test within 14 days of registration; urine human gonadotropin (HCG) is an acceptable pregnancy assessment
Women of child-bearing potential must have a negative serum pregnancy test =< 72 hours prior to initiating treatment
Women of child bearing potential must have a negative serum or urine pregnancy test at the Screening Visit and be non-lactating.
For females of child-bearing potential, negative serum pregnancy test at screening (within 48 hours prior to leukapheresis)
Women of child-bearing potential must have a negative pregnancy test at screening
Women of child-bearing potential must have a negative pregnancy test
For women of child-bearing potential, negative pregnancy test within 14 days prior to starting treatment
Women of child-bearing potential must have a negative pregnancy test
Women of child bearing potential only: Negative urine or serum pregnancy test
Pregnant or breast feeding; females of child-bearing potential must test negative for pregnancy at the time of enrollment
Women of child-bearing potential must have a negative pregnancy test
Pregnant or breast-feeding; urine pregnancy test will be assessed at the baseline visit in women of child-bearing potential with chronic pain
Negative pregnancy test for women of child-bearing potential
For women of child-bearing potential, negative serum pregnancy test within 14 days prior to registration
Subjects of child bearing potential must have a negative urine pregnancy test within 5 days prior to first dose of the study drug
Current or planned pregnancy or lactation in women of child bearing age (confirmed by negative pregnancy test prior to start of therapy)
Patients must not be pregnant; women of child-bearing potential must also have a negative pregnancy test within 2 weeks prior to start of protocol therapy (radiation and veliparib)
Negative pregnancy test (serum or urine) for women of child bearing potential; all protocol participants must agree to adequate contraception
Women of child-bearing potential must have a negative pregnancy test
For women of child bearing potential (women who are not free from menses for > 2 years, post hysterectomy/oophorectomy, or surgically sterilized) a negative serum pregnancy test must be documented prior to initial registration
Breast-feeding or pregnant; serum pregnancy test for women of child-bearing potential must be performed within 7 days prior to first dose of study treatment
Negative serum pregnancy test for women of child-bearing potential
Women of child-bearing potential must not be pregnant and must have a negative pregnancy test; men and women must agree to practice effective contraception while on this study
Negative pregnancy test for women of child-bearing age
Women of child-bearing potential must have a negative pregnancy test within 7 days of initiating study; (no childbearing potential is defined as age 55 years or older and no menses for two years or any age with surgical removal of the uterus and/or both ovaries)
Women of child bearing age must be using adequate birth control and have a negative pregnancy test
Women of child-bearing age must be using adequate birth control and have a negative pregnancy test
Pregnant women are excluded; therefore negative pregnancy test is required for all women of child-bearing age, and appropriate contraception is used during the study period
Patients who are pregnant; negative pregnancy test is required for all women of child-bearing age, and appropriate contraception is required during the study period
Females of child-bearing potential must have a negative pregnancy test within 7 days prior to registration
Females of child-bearing potential must have negative serum pregnancy test within 72 hours before randomization.
Child bearing age women with positive pregnancy test
Women of child-bearing potential must have a negative pregnancy test because of the potentially dangerous effects of the treatment on the fetus
Pregnant or breastfeeding - The agents used in this study include those that fall under Pregnancy Category D - have known teratogenic potential. Women of child bearing potential must have a negative pregnancy test at screening
Women of child-bearing potential must have a negative serum pregnancy test within 7 days prior to first dose of abemaciclib
Negative pregnancy test in women of child bearing potential
Females of child-bearing potential* must have a negative pregnancy test.
Negative urine or serum pregnancy test done =< 7 days prior to registration for females of child bearing potential only
Negative serum pregnancy test result in women of child-bearing potential (WOCBP)
Negative pregnancy test for women with child-bearing potential
Negative serum pregnancy test result for females of child bearing potential
Negative pregnancy test for women of child bearing potential
Evidence of non-child-bearing status for women of childbearing potential; negative urine or serum pregnancy test within 28 days of study treatment, confirmed prior to treatment on day 1
All women of child-bearing potential who take ribavirin will need to have a negative pregnancy test
Women of child bearing potential must have a negative pregnancy test
For females of child-bearing potential, negative serum pregnancy test within 30 days prior to registration
Pregnant or lactating – women of child bearing potential must have a negative pregnancy test within 14 days of study treatment start
Women of child-bearing potential must have a negative pregnancy test
For women of child bearing potential, a negative serum pregnancy testing will be verified within 14 days prior to pre chemotherapy apheresis
Females of child-bearing potential must have a negative pregnancy test
Women must: have a negative serum or urine pregnancy test within 7 days prior to study entry if she is a woman of child-bearing potential (WOCBP), or be at least one year post-menopausal, OR be surgically sterile
Negative pregnancy test (serum or urine) within 10 days of registration in women of child-bearing potential
Negative serum or urine pregnancy test for females of child bearing potential
If the patient is a woman of child bearing potential (WOCBP), she has had a negative serum or urine pregnancy test within 1 week prior to treatment.
If the patient is a woman of child bearing potential (WOCBP), she has had a negative serum or urine pregnancy test within 1 week prior to treatment.
Negative pregnancy test for women of child bearing potential
Females with child-bearing potential must have had a negative serum pregnancy test result =< 28 days prior to the first dose of study treatment
Women of child-bearing potential must have a negative serum pregnancy test within 14 days prior to randomization
Women of child-bearing potential (WOCBP) must have a negative pregnancy test at screening and must agree to use protocol defined methods of contraception for the duration of the study (see below)
For females of child-bearing potential, negative serum/urine pregnancy test within 14 days prior to study registration
Negative pregnancy test for all females of child bearing potential
In women of child-bearing potential, negative serum pregnancy test within 14 days of the first infusion of G-202
Woman of child-bearing potential has negative pregnancy test before the initiation of study drug dosing
Women of child bearing potential must have a negative serum pregnancy test.
If a woman of child bearing potential (WOCBP), she has had a negative serum or urine pregnancy test within 2 weeks prior to treatment.
For women of child-bearing potential, a negative urine pregnancy test
Women of child bearing potential must not be pregnant; a pre-study pregnancy test must be negative
Females of child-bearing potential using contraception; negative pregnancy test
Females of child-bearing potential must have a negative serum pregnancy test within 7 days prior to randomization.
Pregnant and nursing women are excluded; men and women of child-bearing potential are eligible but must consent to using effective contraception during therapy and for at least 3 months after completing therapy; women with child-bearing potential must have a negative serum or urine beta-human chorionic gonadotropin (B-hCG) pregnancy test at screening
Women of child-bearing potential must have a negative pregnancy test within 7 days of initiating study; (no childbearing potential is defined as age 55 years or older and no menses for two years or any age with surgical removal of the uterus and/or both ovaries)
A negative pregnancy test will be required for all women of child bearing potential; breast feeding is not permitted
Negative serum pregnancy test for women of child-bearing potential
Patients with child-bearing potential must have a negative urine pregnancy test within 7 days prior to registration
A negative serum pregnancy test obtained within 4 weeks prior to the start of treatment in all women of child-bearing potential
Women of child-bearing potential must have a negative (urine or blood) pregnancy test within 6 weeks prior to start of protocol therapy; women of child-bearing potential must also use effective non-hormonal contraception while undergoing radiation therapy
Negative serum pregnancy test within 14 days prior to study treatment if a woman has child-bearing potential. Subjects of child bearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year.
Negative pregnancy test for women with child-bearing potential
For women: Negative pregnancy test for females of child-bearing potential; must be surgically sterile, postmenopausal, or compliant with a contraceptive regimen during and for 3 months after the treatment period
Patient refuses to take a pregnancy test prior to treatment if the patient is a woman with child bearing potential
In women of child-bearing potential, negative serum pregnancy test within 48 hours prior to day 1 of study treatment and agree to use effective contraception
Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days and will also need to use contraceptives; men must agree not to father a child and agree to use a condom if his partner is of child bearing potential
Women of child bearing potential must undergo pregnancy testing within 7 days of the first dose of study therapy; women must also undergo pregnancy test at 6 months after the last dose
Woman of child-bearing potential has negative pregnancy test before the initiation of study drug dosing
Negative urine pregnancy test within one week before starting treatment in women of child-bearing potential
Women must:\r\n* Have a negative serum or urine pregnancy test within 7 days prior to study entry if she is a woman of child-bearing potential, OR\r\n* Be at least one year post-menopausal, OR\r\n* Be surgically sterile
Negative pregnancy test in women of child-bearing potential
Women of child-bearing potential must have a negative pregnancy test
Females with child bearing potential must have a negative serum pregnancy test within 3 days of the first dose of study drug
Pregnant or breastfeeding; women of child bearing potential must have a negative pregnancy test within 14 days of study treatment start
Negative urine or serum pregnancy test done =< 7 days prior to randomization, for women of child bearing potential only
Women of child bearing potential must have a negative pregnancy test
Pregnancy in women of child bearing potential (pregnancy test performed within 2 weeks of study entry)
Women of child bearing potential having a positive urine or serum pregnancy test (hCG) at the time of pre-operative evaluation (within 7 days of surgery)
Pregnant women are excluded for fear of danger to the fetus; therefore negative pregnancy test is required for all women of child-bearing age, and appropriate contraception is required during the study period
Women of child-bearing potential must have a negative pregnancy test
Subjects who are women of child-bearing potential must not be pregnant or lactating, must have a negative pregnancy test at Day 0.
Negative serum pregnancy test for women of child-bearing potential
Negative pregnancy test for women of child-bearing potential.
Women of child bearing potential must have a negative pregnancy test and use reliable methods of contraception
Patients with child bearing potential must have a negative pregnancy test (urine or serum) prior to study treatment
Females who are pregnant or lactating may not participate in this study; females of child-bearing potential must have a negative pregnancy test before starting study agent; patients who have had a bilateral oophorectomy, hysterectomy, or are greater than 1 year since their last menses are not considered to be of child-bearing potential
Women of child-bearing potential must have a negative pregnancy test
Women of child-bearing potential must have a negative pregnancy test
Women of child-bearing potential will be required to undergo a negative pregnancy test prior to enrollment, and women who are currently pregnant will not be considered eligible
Females of child-bearing potential must have a negative serum test Participation in concurrent clinical trials
Females must be either non-child bearing potential or have a negative pregnancy test within 3 to 5 days prior to the first dose of study drug.
Women of child-bearing age must have a negative, quantitative serum pregnancy test =< 14 days prior to study entry, or have a documented reason why such a test is not necessary (e.g. history of tubal ligation)
Women of child-bearing potential must have a negative pregnancy test within 7 days of initiating study; (no childbearing potential is defined as age 55 years or older and no menses for two years or any age with surgical removal of the uterus and/or both ovaries)
Women of child-bearing age must have a negative pregnancy test
Women of child bearing potential must have a negative serum pregnancy test
For women of child-bearing potential, negative pregnancy test within 14 days prior to starting treatment
Pregnant or lactating women. Women of child-bearing potential (WOCBP) must have a negative serum pregnancy test documented within 72 hours prior to starting study drug or a urine pregnancy test shall be done on Day 1 of Cycle 1
Women of child bearing potential must have a negative pregnancy test
Women of child bearing potential (WOCBP) must have a negative serum or urine pregnancy test within 5 days prior to randomization.
Women of child-bearing potential must have a negative serum pregnancy test within 7 days prior to date of study entry; women who have had menses within the past 2 years, who have not had a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy are considered to be of child-bearing potential; patients with elevated human chorionic gonadotropin (hCG) at baseline that is judged to be related to the tumor are eligible if hCG levels do not show the expected doubling when repeated 5-7 days later, or pregnancy has been ruled out by vaginal ultrasound
Women of child bearing potential must have a negative serum or urine pregnancy test at the Screening Visit and be non-lactating.
Positive pregnancy test in women of child-bearing potential.
Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days; men must agree not to father a child and agree to use a condom if his partner is of child bearing potential
Serum pregnancy test for women of child bearing potential must be negative at entry into study
The patient is a woman of child bearing potential (WOCBP) who has had a negative serum or urine pregnancy test within 1 week prior to SL-401 treatment (intervals shorter than 1 week are acceptable if required by institutional guidelines).
Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days and will also need to use contraceptives; men must agree not to father a child and agree to use a condom if his partner is of child bearing potential
Women of child-bearing potential must have a negative pregnancy test within 14 days prior to commencement of study treatment
Women of child-bearing potential must have a negative pregnancy test
Women of child-bearing potential must have a negative pregnancy test
Women of child-bearing potential must have a negative pregnancy test.
Negative pregnancy test (urinary or serum beta-HCG) at screening (applicable to women of child bearing potential who are sexually active)
Females must either be of non-child bearing potential or have a negative serum pregnancy test within 7 days prior to the first dose of study treatment.
Women of child bearing potential must not be pregnant; a pre-study pregnancy test must be negative
Pregnancy or lactation; all females of child-bearing potential must have negative serum or urine pregnancy tests within 7 days prior to starting study treatment
Women of child-bearing potential must have a negative pregnancy test within 14 days prior to the first dose of study treatment.
Women of child-bearing potential must have a negative pregnancy test
Women of child-bearing potential must have a negative pregnancy test
Pregnancy test for females of child-bearing potential
For women of child-bearing potential, negative serum pregnancy test within 14 days prior to registration
Women of child-bearing potential must have a negative pregnancy test prior to initiating study treatment
Women of child bearing potential between the ages of 18 and 60 years of age must have a negative urine pregnancy test prior to undergoing simulation in preparation for radiation therapy to the pelvis
Negative serum/urine pregnancy test within 24 hours for females of child bearing age prior to surgery
Women of child bearing potential with a negative urine or blood pregnancy test within a month of enrollment (only for patients who are going to be randomized to either therapeutic arms)
Women of child-bearing age must have a negative, quantitative serum pregnancy test =< 14 days prior to study entry, or have a documented reason why such a test is not necessary (e.g. history of tubal ligation)
If the patients is of child bearing potential, the patient has a negative pregnancy test within 72 hours prior to administration of radiopharmaceutical, has been surgically sterilized, or has been postmenopausal for at least 1 year
Pregnant or nursing women - women of child?bearing potential must have negative serum or urine pregnancy test
Pregnancy or lactation; negative pregnancy test is required within the screening window for women of child bearing potential
Women of child-bearing potential must have a confirmed negative pregnancy test result prior to enrollment
Pregnant or breastfeeding; women of child bearing potential must have a negative pregnancy test at screening
Females of child-bearing potential must have a negative pregnancy test within the current menstrual cycle and within 7 days before starting drug
Negative urine pregnancy test within 2 weeks of registration for women of child-bearing potential; women of child-bearing potential must have a documented negative pregnancy test and agree to use adequate contraception throughout the study period
Women of child-bearing potential must have a negative pregnancy test within one week of IORT treatment
Females of child bearing age must have a negative serum pregnancy test within 7 days of first dose of study drug
Females of child-bearing potential must have a negative pregnancy test within the current menstrual cycle and within 7 days before starting drug
Negative serum pregnancy test, if of child-bearing potential
Negative serum pregnancy test for women of child bearing potential (WOCBP)
Females who are pregnant at the time of screening will not be eligible for this study, urine or serum pregnancy test will be performed in women of child-bearing potential at the time of screening
Women of child-bearing potential must have a negative urinary or serum pregnancy test within 7 days of baseline imaging
Females who are pregnant at the time of screening will not be eligible for this study, urine or serum pregnancy test will be performed in women of child-bearing potential at the time of screening
Women of child bearing potential must have a negative serum pregnancy test
PATIENT: If of child-bearing potential, must have a negative pregnancy test
Females who are pregnant at the time of screening will not be eligible for this study, urine pregnancy test will be performed at screening in women of child-bearing potential
Women of child bearing potential with negative pregnancy test documented
Negative pregnancy test for women of child-bearing potential
Negative urine pregnancy test in women of child-bearing potential
Women of child-bearing potential must have a negative blood pregnancy test at screening and use an adequate and medically acceptable contraceptive method.
Negative serum pregnancy test for women of child bearing potential
Negative serum pregnancy test for females of child-bearing age (11-50 years) and potential (ie, women who were not postmenopausal before the start of ongoing treatment, if applicable; and who have not had a surgical intervention whose intent or effect is sterilization, such as tubal ligation or hysterectomy)
Women of child bearing potential must have a negative serum pregnancy test no more than 72 hours prior to registration
Negative urine pregnancy test in women of child-bearing potential (WCBP) within 1 week prior to s-DCT
Negative pregnancy test if of child-bearing age
Women of child-bearing age will be asked to undergo a pregnancy test prior to enrollment
Patients who are pregnant or breast feeding; urine pregnancy test will be performed on women of child bearing potential
Patients of child-bearing potential must have a negative urine or serum pregnancy test
Women who are not of child-bearing potential, and women of child-bearing potential who agree to use adequate contraceptive measures during the study and for 90 days after the last dose of study medication, and who have a negative serum or urine pregnancy test within 1 week prior to initial trial treatment.
Females should be using adequate contraceptive measures, not be breast feeding and must have negative pregnancy test prior to start of dosing if of child-bearing potential
Female patients who are not of child-bearing potential and fertile females of childbearing potential who agree to use adequate contraceptive measures from 2 weeks prior to the study and until 1 month after study treatment discontinuation, who are not breastfeeding, and who have a negative serum or urine pregnancy test within 3 days prior to the start of study treatment
Females of child-bearing potential should be using adequate contraceptive measures throughout the study, should not be breast feeding at the time of screening, during the study and until 3 months after completion of study, and must have a negative pregnancy test prior to start of dosing if of child-bearing potential or must have evidence of non-child-bearing potential by fulfilling 1 of the following criteria at screening:
Females should be using adequate contraceptive measures from the time of screening until 3 months after study discontinuation, should not be breast feeding and must have negative pregnancy test prior to the start of dosing.
Females with child bearing age should be using adequate contraceptive measures, should not be breast feeding and must have a negative pregnancy test prior to the start of dosing
Females should be using adequate contraceptive measures, should not be breast feeding, and must have a negative pregnancy test prior to start of dosing if of childbearing potential or must have evidence of non-child-bearing potential by fulfilling one of the following criteria at screening:
Females must be using adequate contraceptive measures, must not be breast feeding and must have a negative pregnancy test prior to start of dosing if of child-bearing potential or must have evidence of non-child-bearing potential
Females of child-bearing potential willing to use adequate contraceptive measures from the time of screening until 6 months after trial discontinuation, who are not or will not be breast feeding, and agree to have pregnancy tests prior to the start of dosing and at regular visits during the trial. Females not of childbearing potential must have evidence of such by fulfilling one of the following criteria at screening:
Female patients should be using adequate contraceptive measures, should not be breast feeding, and must have a negative pregnancy test prior to first dose of study drug; or female patients must have an evidence of non-child-bearing potential.
Female patients should be using highly effective contraceptive measures, and must have a negative pregnancy test prior to start of dosing if of childbearing potential
childbearing potential without proper contraceptive measures, pregnancy, or breast feeding;
Women who are not of child-bearing potential and fertile females of childbearing potential who agree to use adequate contraceptive measures, who are not breastfeeding, and who have a negative serum pregnancy test within 3 days prior to the start of study treatment.
Women should be using adequate contraceptive measures, should not be breast feeding and must have a negative pregnancy test before start of dosing if of child-bearing potential or must have evidence of nonchildbearing potential.
Females should agree to use adequate contraceptive measures, should not be breast feeding and must have a negative pregnancy test prior to start of dosing if of child-bearing potential or must have evidence of non-child-bearing potential
Females should be using adequate contraceptive measures should not be breast feeding, and must have a negative pregnancy test prior to start of dosing if of childbearing potential or must have evidence of non-childbearing potential
Females should be using adequate contraceptive measures, should not be breast feeding and must have a negative pregnancy test prior to start of dosing or evidence of non-child bearing potential.
For women of childbearing potential, the participant must have a negative pregnancy test at screening and must agree to employ 2 forms of adequate contraceptive measures
